Login
Rockwell Medical NASDAQ: RMTI
Rockwell Medical operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases
| Name | Rockwell Medical |
| Ticker | RMTI |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Kidney Failure |
| Price | 0.96 |
| 52W Low/High | 0.96 / 3.57 |
| Market cap | 66 M |
| 1Y Total Return |
-60.33%
Weak |
| 1Y Volatility |
100.52%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Rockwell Medical operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases
Details
| Ticker | RMTI |
| Name | Rockwell Medical |
| ISIN | US7743741024 |
| CUSIP | 774374102 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Kidney Failure |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 10/23/20
| Close Price | 0.96 |
| 52W Low/High | 0.96 / 3.57 |
| Market cap | 66 M |
| 1Y Total Return |
-60.33%
Weak |
| 1Y Volatility |
100.52%
High Risk |
| Beta | 0.28 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -47.9% |
| Cash from Op. / Cur. Liabilities | -2.40 |
| Diluted Earnings / Share | -0.45 |
| ROE | - |
| ROIC | -142.7% |
| Price / Revenue | 1.1 |
| Price / Book | 4.1 |
| Price / CF | -2.4 |
| Current Ratio | 4.5 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 1.36 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
63
|
64
|
59
|
54
|
56
|
55
|
|
| Gross Profit |
3
|
5
|
-
|
7
|
8
|
9
|
|
| R&D |
7
|
7
|
7
|
5
|
7
|
5
|
|
| EBITDA |
-27
|
-32
|
-31
|
-21
|
-17
|
-13
|
|
| Operating Income |
-29
|
-34
|
-32
|
-22
|
-19
|
-15
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
69
|
58
|
51
|
-
|
-
|
-
|
|
| EPS exc. Extra |
-0.45
|
-0.60
|
-0.63
|
-0.42
|
-0.38
|
-0.37
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
59
|
57
|
41
|
69
|
87
|
92
|
|
| Cash, Eq & Invt ShortTerm |
40
|
35
|
23
|
43
|
64
|
77
|
|
| Total Current Assets |
52
|
48
|
36
|
64
|
84
|
88
|
|
| Total Non-Current Assets |
7
|
9
|
6
|
6
|
3
|
3
|
|
| Intangibles |
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Liabilities |
42
|
27
|
25
|
26
|
30
|
26
|
|
| Total Current Liabilities |
11
|
15
|
11
|
8
|
9
|
7
|
|
| Long Term Debt |
31
|
13
|
13
|
18
|
20
|
19
|
|
| Shareholder equity |
16
|
30
|
17
|
44
|
58
|
66
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-28
|
-26
|
-19
|
-18
|
-10
|
8
|
|
| Depreciation |
2
|
2
|
1
|
1
|
1
|
1
|
|
| Cash from Investing |
0
|
6
|
12
|
5
|
-2
|
-32
|
|
| Capex |
1
|
1
|
2
|
1
|
1
|
0
|
|
| Cash from Financing |
33
|
40
|
0
|
-2
|
-2
|
58
|
|
| Stock Issued |
14
|
40
|
-2
|
0
|
1
|
79
|
|
| Debt (LT) Issued |
19
|
0
|
0
|
0
|
0
|
-21
|
|
| Free Cash Flow |
-29
|
-28
|
-21
|
-25
|
-25
|
-23
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
4.5
|
3.3
|
3.2
|
8.3
|
9.1
|
12.6
|
|
| Financial Leverage D/E |
1.36
|
0.12
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-142.7%
|
-135.3%
|
-77.8%
|
-39.8%
|
-36.3%
|
-51.4%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available